


- 30 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice  
31 and in accordance with the dossier submitted.
- 32 Failure to comply with these provisions will render this certificate void.
- 33 This certificate is renewed from **4 November 2015** according to the provisions of Resolution  
34 AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent  
35 amendment, and the related guidelines.
- 36 This certificate has two annexes, the first of 1 page and the second of 5 pages.
- 37 This certificate has:
- 38 lines.

  
On behalf of the  
Director of EDQM



Strasbourg, 12 September 2019

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

**IOL CHEMICALS AND PHARMACEUTICALS LTD**, as holder of the certificate of suitability

**R1-CEP 2008-316-Rev 03 for Ibuprofen**

UAB "Corpus Medica"  
hereby authorises 61-2 Sukileliu ave, LT-49333, Kaunas,  
*(name of the pharmaceutical company)* Lithuania

to use the above-mentioned certificate of suitability in support of their application(s) for the following  
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

Tringestin 400mg film-coated Tablets

The holder also certifies that no significant changes to the operations as described in the CEP dossier  
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*:

**For IOL Chemicals and Pharmaceuticals Ltd**

Name - Kushal Kumar Rana  
(President Quality)

17.06.2020  
**Authorized Signatory**

Address: 7 Allée Kastner, CS 30026  
F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 – e-mail: cep@edqm.eu

Internet: <http://www.edqm.eu>